Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 5;110(1):3-12.
doi: 10.1016/j.ajhg.2022.12.004.

Genotype first: Clinical genomics research through a reverse phenotyping approach

Affiliations
Review

Genotype first: Clinical genomics research through a reverse phenotyping approach

Caralynn M Wilczewski et al. Am J Hum Genet. .

Abstract

Although genomic research has predominantly relied on phenotypic ascertainment of individuals affected with heritable disease, the falling costs of sequencing allow consideration of genomic ascertainment and reverse phenotyping (the ascertainment of individuals with specific genomic variants and subsequent evaluation of physical characteristics). In this research modality, the scientific question is inverted: investigators gather individuals with a genomic variant and test the hypothesis that there is an associated phenotype via targeted phenotypic evaluations. Genomic ascertainment research is thus a model of predictive genomic medicine and genomic screening. Here, we provide our experience implementing this research method. We describe the infrastructure we developed to perform reverse phenotyping studies, including aggregating a super-cohort of sequenced individuals who consented to recontact for genomic ascertainment research. We assessed 13 studies completed at the National Institutes of Health (NIH) that piloted our reverse phenotyping approach. The studies can be broadly categorized as (1) facilitating novel genotype-disease associations, (2) expanding the phenotypic spectra, or (3) demonstrating ex vivo functional mechanisms of disease. We highlight three examples of reverse phenotyping studies in detail and describe how using a targeted reverse phenotyping approach (as opposed to phenotypic ascertainment or clinical informatics approaches) was crucial to the conclusions reached. Finally, we propose a framework and address challenges to building collaborative genomic ascertainment research programs at other institutions. Our goal is for more researchers to take advantage of this approach, which will expand our understanding of the predictive capability of genomic medicine and increase the opportunity to mitigate genomic disease.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests L.G.B. is a member of the Illumina Medical Ethics Board and receives honoraria from Cold Spring Harbor Laboratory Press, royalties from Invitae, Inc., and research support from Merck, Inc.

Figures

None
Graphical abstract
Figure 1
Figure 1
Research approaches to formulate and test human genotype-phenotype relationships Clinical genetics research has primarily relied on three approaches to discern the relationship between genetic variation and human traits: phenotypic ascertainment, which uses a cohort of phenotypically similar individuals to identify an underlying genetic cause; clinical informatics, which tests associations between known genotypes and previously recorded clinical data typically stored in the electronic health record (EHR); and more recently reverse phenotyping, which targets recruitment to individuals with known genotypes to collect new phenotypic data.

References

    1. Moresco E.M.Y., Li X., Beutler B. Going forward with genetics: recent technological advances and forward genetics in mice. Am. J. Pathol. 2013;182:1462–1473. - PMC - PubMed
    1. Altshuler D., Daly M.J., Lander E.S. Genetic mapping in human disease. Science (New York, N.Y.) 2008;322:881–888. - PMC - PubMed
    1. Nannenberg E.A., van Rijsingen I.A.W., van der Zwaag P.A., van den Berg M.P., van Tintelen J.P., Tanck M.W.T., Ackerman M.J., Wilde A.A.M., Christiaans I. Effect of ascertainment bias on estimates of patient mortality in inherited cardiac diseases. Circ. Genom. Precis. Med. 2018;11:e001797. - PubMed
    1. Ranola J.M.O., Tsai G.J., Shirts B.H. Exploring the effect of ascertainment bias on genetic studies that use clinical pedigrees. Eur. J. Hum. Genet. 2019;27:1800–1807. - PMC - PubMed
    1. Brohet R.M., Velthuizen M.E., Hogervorst F.B.L., Meijers-Heijboer H.E.J., Seynaeve C., Collée M.J., Verhoef S., Ausems M.G.E.M., Hoogerbrugge N., van Asperen C.J., et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J. Med. Genet. 2014;51:98–107. - PubMed

Publication types